This web site is part of the Business Intelligence Division of Informa PLC
This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.
Drug Names(s): epoprostenol sodium
Description: The active agent in Flolan is epoprostenol, a potent vasodilator and inhibitor of platelet aggregatation that exerts its activity through the prostacyclin receptor. Used as a treatment for pulmonary arterial hypertension (PAH), it relaxes the blood vessels in the lungs and slows the process of scarring and cell growth within the lung’s blood vessels, preventing further narrowing. It also assists in increasing cardiac output and oxygen saturation. It improves exercise tolerance and prolongs survival in patients with PAH.
Deal Structure: In March 2006, GlaxoSmithKline (GSK) and Myogen entered into a distribution agreement whereby Myogen will be responsible for the marketing and distribution of Flolan in the United States. The distribution agreement is a three-year agreement with an option to renew upon mutual consent.
Gilead announced it completed of its cash tender offer for all of the outstanding shares of common stock of Myogen on November 14th, 2006. On October 2, 2006, Gilead and Myogen entered into a definitive merger agreement for Gilead to acquire all of the outstanding shares of common stock of Myogen for $52.50 in cash per share.
In March 2009, Gilead terminated its agreement with GlaxoSmithKline.
Pink Sheet In Brief: Wellcome's Flolan
Pink Sheet Burroughs Wellcome’s Flolan
Additional information available to subscribers only: